ATE425463T1 - Modulation der wechselwirkung zwischen hgf-beta- kette und c-met - Google Patents
Modulation der wechselwirkung zwischen hgf-beta- kette und c-metInfo
- Publication number
- ATE425463T1 ATE425463T1 AT04754499T AT04754499T ATE425463T1 AT E425463 T1 ATE425463 T1 AT E425463T1 AT 04754499 T AT04754499 T AT 04754499T AT 04754499 T AT04754499 T AT 04754499T AT E425463 T1 ATE425463 T1 AT E425463T1
- Authority
- AT
- Austria
- Prior art keywords
- met
- modulation
- interaction
- beta chain
- hgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47677803P | 2003-06-06 | 2003-06-06 | |
US53211703P | 2003-12-23 | 2003-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE425463T1 true ATE425463T1 (de) | 2009-03-15 |
Family
ID=33555430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04754499T ATE425463T1 (de) | 2003-06-06 | 2004-06-04 | Modulation der wechselwirkung zwischen hgf-beta- kette und c-met |
Country Status (17)
Country | Link |
---|---|
US (8) | US20060035278A9 (de) |
EP (3) | EP2367008A3 (de) |
JP (1) | JP2007526447A (de) |
KR (2) | KR20110117728A (de) |
AT (1) | ATE425463T1 (de) |
AU (1) | AU2004252475A1 (de) |
CA (1) | CA2528343A1 (de) |
DE (1) | DE602004019919D1 (de) |
DK (1) | DK1636593T5 (de) |
ES (1) | ES2323425T3 (de) |
HK (1) | HK1092872A1 (de) |
HR (1) | HRP20090324T1 (de) |
MX (1) | MXPA05013181A (de) |
PL (1) | PL1636593T3 (de) |
PT (1) | PT1636593E (de) |
SI (1) | SI1636593T1 (de) |
WO (1) | WO2005001486A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
RS53476B (en) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Hepatocyte Growth Factor Binders |
JP2008516629A (ja) | 2004-10-20 | 2008-05-22 | ペアス インスティテュート アーベー | 肝細胞増殖因子(hgf)の生物活性に関する評価 |
RU2547148C2 (ru) | 2005-02-09 | 2015-04-10 | Аркьюл, Инк. | Композиции и способы лечения рака |
ES2539790T3 (es) * | 2005-03-25 | 2015-07-06 | Genentech, Inc. | Métodos y composiciones para modular c-met hiperestabilizado |
AU2006229990A1 (en) * | 2005-03-25 | 2006-10-05 | Genentech, Inc. | C-met mutations in lung cancer |
SG161281A1 (en) | 2005-04-15 | 2010-05-27 | Genentech Inc | Hgf beta chain variants |
AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
JP2010513566A (ja) | 2006-12-19 | 2010-04-30 | ジェネンテック, インコーポレイテッド | アジュバント療法およびネオアジュバント療法のためのvegf特異的アンタゴニストと初期ステージ腫瘍の治療 |
JP2010530885A (ja) | 2007-06-22 | 2010-09-16 | アークル インコーポレイテッド | キナゾリノン化合物およびその使用方法 |
JP5425060B2 (ja) | 2007-06-22 | 2014-02-26 | アークル インコーポレイテッド | ピロリジノン、ピロリジン−2,5−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法 |
EP2173748B1 (de) | 2007-06-22 | 2011-08-31 | ArQule, Inc. | Indolylpyrrolidine zur behandlung von krebs |
AU2008323719B2 (en) * | 2007-11-09 | 2013-04-04 | New York Medical College | Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor |
TW200940064A (en) * | 2008-03-06 | 2009-10-01 | Genentech Inc | Combination therapy with C-MET and EGFR antagonists |
US9157920B2 (en) * | 2009-06-26 | 2015-10-13 | Peas Institut Ab | Method for determining biologically active HGF |
JP5814925B2 (ja) | 2009-10-22 | 2015-11-17 | ジェネンテック, インコーポレイテッド | 抗ヘプシン抗体及びその使用方法 |
KR102059663B1 (ko) | 2010-03-10 | 2019-12-26 | 젠맵 에이/에스 | C―met에 대한 모노클로날 항체 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CN102643268B (zh) | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
WO2013143376A1 (zh) | 2012-03-26 | 2013-10-03 | 武汉盛云生物医药科技有限责任公司 | 含1,2,4-三嗪-3,5-二酮的喹啉类化合物及其应用 |
ES2530968T3 (es) | 2012-10-12 | 2015-03-09 | Spirogen Sarl | Pirrolobenzodiazepinas y conjugados de las mismas |
CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
CN113150147A (zh) | 2015-03-16 | 2021-07-23 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドMedImmune Limited | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
EP3796942A1 (de) | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molekulares adjuvans |
JP7380999B2 (ja) * | 2018-09-06 | 2023-11-15 | 国立大学法人 東京大学 | 環状ペプチド |
CN114340684A (zh) | 2019-09-16 | 2022-04-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6344321B1 (en) * | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
EP0584125B1 (de) * | 1991-05-10 | 1997-07-16 | PHARMACIA & UPJOHN S.p.A. | Verkürzte Formen den Hepatozyten Wachstumsfaktor (HGF) Rezeptors |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5328837A (en) * | 1992-05-18 | 1994-07-12 | Genentech, Inc. | Hepatocyte growth factor protease domain variants |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
AU695323B2 (en) | 1994-09-09 | 1998-08-13 | Takeda Chemical Industries Ltd. | Sustained release preparation containing metal salt of a peptide |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5647409A (en) | 1995-04-04 | 1997-07-15 | Allergan | On-site syringe filling apparatus for viscoelastic materials, and corresponding method for on-site syringe filling |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
PT831787E (pt) | 1995-06-07 | 2002-02-28 | Alkermes Inc | Composicao para libertacao sustentada da hormona de crescimento humano |
ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US5911252A (en) | 1997-04-29 | 1999-06-15 | Cassel; Douglas | Automated syringe filling system for radiographic contrast agents and other injectable substances |
US6677377B2 (en) * | 2000-06-21 | 2004-01-13 | Georgetown University School Of Medicine | Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions |
-
2004
- 2004-06-04 DK DK04754499T patent/DK1636593T5/da active
- 2004-06-04 KR KR1020117022830A patent/KR20110117728A/ko not_active Application Discontinuation
- 2004-06-04 EP EP20100009373 patent/EP2367008A3/de not_active Withdrawn
- 2004-06-04 PL PL04754499T patent/PL1636593T3/pl unknown
- 2004-06-04 KR KR1020057023299A patent/KR101148657B1/ko not_active IP Right Cessation
- 2004-06-04 ES ES04754499T patent/ES2323425T3/es not_active Expired - Lifetime
- 2004-06-04 DE DE602004019919T patent/DE602004019919D1/de not_active Expired - Lifetime
- 2004-06-04 AT AT04754499T patent/ATE425463T1/de active
- 2004-06-04 US US10/862,192 patent/US20060035278A9/en not_active Abandoned
- 2004-06-04 EP EP04754499A patent/EP1636593B9/de not_active Revoked
- 2004-06-04 JP JP2006515232A patent/JP2007526447A/ja active Pending
- 2004-06-04 AU AU2004252475A patent/AU2004252475A1/en not_active Abandoned
- 2004-06-04 PT PT04754499T patent/PT1636593E/pt unknown
- 2004-06-04 WO PCT/US2004/017901 patent/WO2005001486A1/en active Application Filing
- 2004-06-04 SI SI200431128T patent/SI1636593T1/sl unknown
- 2004-06-04 CA CA002528343A patent/CA2528343A1/en not_active Abandoned
- 2004-06-04 MX MXPA05013181A patent/MXPA05013181A/es active IP Right Grant
- 2004-06-04 EP EP20090002616 patent/EP2093570A1/de not_active Withdrawn
-
2006
- 2006-10-02 US US11/537,753 patent/US20070129301A1/en not_active Abandoned
- 2006-12-12 HK HK06113627.8A patent/HK1092872A1/xx not_active IP Right Cessation
-
2009
- 2009-06-02 HR HR20090324T patent/HRP20090324T1/hr unknown
- 2009-10-21 US US12/582,934 patent/US20100040634A1/en not_active Abandoned
-
2010
- 2010-12-22 US US12/975,828 patent/US20110177058A1/en not_active Abandoned
-
2011
- 2011-12-07 US US13/313,983 patent/US20130143813A1/en not_active Abandoned
-
2014
- 2014-06-26 US US14/316,621 patent/US20150126448A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/162,372 patent/US20170106042A1/en not_active Abandoned
-
2018
- 2018-03-15 US US15/921,827 patent/US20190054138A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20060017634A (ko) | 2006-02-24 |
EP2367008A2 (de) | 2011-09-21 |
US20100040634A1 (en) | 2010-02-18 |
US20110177058A1 (en) | 2011-07-21 |
HK1092872A1 (en) | 2007-02-16 |
KR101148657B1 (ko) | 2012-07-05 |
EP2367008A3 (de) | 2014-12-24 |
EP2093570A1 (de) | 2009-08-26 |
PL1636593T3 (pl) | 2009-08-31 |
EP1636593A1 (de) | 2006-03-22 |
US20190054138A1 (en) | 2019-02-21 |
US20130143813A1 (en) | 2013-06-06 |
EP1636593B1 (de) | 2009-03-11 |
KR20110117728A (ko) | 2011-10-27 |
SI1636593T1 (sl) | 2009-08-31 |
US20060035278A9 (en) | 2006-02-16 |
HRP20090324T1 (hr) | 2010-02-28 |
DE602004019919D1 (de) | 2009-04-23 |
ES2323425T3 (es) | 2009-07-15 |
CA2528343A1 (en) | 2005-01-06 |
PT1636593E (pt) | 2009-06-03 |
US20050037431A1 (en) | 2005-02-17 |
EP1636593B9 (de) | 2009-12-16 |
WO2005001486A1 (en) | 2005-01-06 |
US20070129301A1 (en) | 2007-06-07 |
DK1636593T5 (da) | 2009-07-27 |
US20170106042A1 (en) | 2017-04-20 |
JP2007526447A (ja) | 2007-09-13 |
AU2004252475A1 (en) | 2005-01-06 |
DK1636593T3 (da) | 2009-06-15 |
MXPA05013181A (es) | 2006-06-23 |
US20150126448A1 (en) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE425463T1 (de) | Modulation der wechselwirkung zwischen hgf-beta- kette und c-met | |
NO20075412L (no) | Fremgangsmater og preparater til modulering av hyperstabilisert C-MET | |
ATE529103T1 (de) | Modulation der apolipoprotein c-iii expression | |
DK1685105T3 (da) | Allosteriske modulatorer af metabotropiske glutamatreceptorer | |
ATE512222T1 (de) | Modulation der expression von diacylglycerin- acyltransferase 2 | |
BRPI0411055A (pt) | compostos de heteroarilas contendo nitrogênio e seus usos no aumento da eritropoietina endógena | |
HK1101178A1 (en) | Alkynyl derivatives as modulators of metabotropic glutamate receptors | |
DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
BR0003184A (pt) | Métodos para tratamento de pigmentação da pele | |
WO2003068944A3 (en) | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α- | |
ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
DE60223923D1 (de) | Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke | |
DE60320778D1 (de) | Flüssige Bleichaktivatorzusamensetzung | |
BRPI0515670A (pt) | anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met | |
ATE460923T1 (de) | Lyophilisierung von virosomen | |
DK1250455T3 (da) | Antisense-inhibering af PTP1B-ekspression | |
DK1373503T3 (da) | Neurotrofiske faktorer | |
ATE534649T1 (de) | Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 | |
ATE400273T1 (de) | 1-2'-(1,4'-biperidin-1'-yl)-1-(phenyl)- ethylcyclohexanol-derivate als monoamin- wiederaufnahme-modulatoren zur behandlung von vasomotorischen symptomen | |
UA93886C2 (ru) | Производные четвертичного альфа-аминокарбоксамида kak модуляторы потенциалозависимых натриевых каналов | |
DE59907346D1 (de) | Verwendung von Schwefel-organischen Verbindungen als Mittel zur bathochromen Verschiebung der UV/Vis-Absorptionsbande von Carotinoiden | |
ATE403665T1 (de) | Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1 | |
DE60237756D1 (de) | Zusammensetzungen zur verhinderung der thrombozytenaggregation | |
ATE334692T1 (de) | Kombination von arnica, ruscus und menthol | |
RS52258B (en) | 4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND THEIR USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1636593 Country of ref document: EP |